Regeneron Pharmaceuticals, Inc.can tap into a broader market opportunity in the COVID-19 pandemic with an expansion to the authorization of its two-antibody drug cocktail to include post-exposure prophylaxis against SARS-CoV-2 infection.
The US Food and Drug Administration said 30 July that it had revised the emergency use authorization (EUA) of REGEN-COV...






